- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06384807
Een fase 1/2-studie van PBI-410 bij geavanceerde solide tumoren
Een fase 1/2, eerste in menselijke, dosisescalatie- en dosisuitbreidingsstudie van PBI-410 bij deelnemers met gevorderde solide tumoren
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated, advanced solid tumors. The study comprises 2 parts: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion. The Phase 1 will investigate the safety and tolerability of BHV-1510 given in monotherapy and given in combination with cemiplimab and identify one or more recommended doses for expansion (RDEs) and the maximum-tolerated dose (MTD) (if one exists). Once the RDE has been established, Phase 2 will open to investigate the preliminary efficacy of BHV-1510 in signal-finding expansion cohorts.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Chief Medical Officer
- Telefoonnummer: 203-404-0410
- E-mail: clinicaltrials@biohavenpharma.com
Studie Locaties
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Werving
- Site-113
-
La Jolla, California, Verenigde Staten, 92093
- Werving
- Site-112
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Site-111
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20016
- Werving
- Site-114
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33176
- Werving
- Site-103
-
Orlando, Florida, Verenigde Staten, 32827
- Werving
- Site-105
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Site-115
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30912
- Werving
- Site-110
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Werving
- Site-109
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63108
- Voltooid
- Site-101
-
-
New York
-
New York, New York, Verenigde Staten, 10021
- Werving
- Site-117
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73117
- Werving
- Site-116
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Werving
- Site-108
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Site-107
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75231
- Werving
- Site-104
-
-
Utah
-
West Valley City, Utah, Verenigde Staten, 84119
- Werving
- Site-106
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- Site-102
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
-
Male or female participants aged ≥18 years.
-
Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.
-
Measurable disease (per RECIST 1.1).
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
-
Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):
- Hemoglobin ≥9 g/dL
- Absolute neutrophil count >1,500/mm3; participants with known Duffy null phenotype who have absolute neutrophil count ≥1,200/mm3 may be enrolled
- Platelets >100,000/mm3
- Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.
- Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)
- Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)
- International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN
- Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
-
Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
BHV-1510 in Combination with specific inclusion criteria:
- histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot betreated with curative intent) or metastatic cancer including Endometrial Carcinoma that is confirmed as proficient mismatch repair (pMMR)
- received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.
Key Exclusion Criteria:
- Women who are pregnant or lactating.
- Clinically significant intercurrent disease.
- Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.
- Has clinically significant corneal disease.
- Requires supplemental oxygen for daily activities.
- Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
- Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.
- Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone and visceral metastasis therapy. Any major surgical procedure within 6 weeks prior to C1D1.
- History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.
- Has current or previously treated leptomeningeal carcinomatosis.
- Use of OAP1B1 and OATP1B3 inhibitors within 14 days prior to starting trial.
BHV-1510 in Combination Specific Exclusion Criteria:
- Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.
- Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
- Prior allogeneic stem cell or solid organ transplantation.
- Patients with history of myocarditis.
- Presence of cardiovascular disease
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: BHV-1510 Dosisescalatie voor monotherapie
|
BHV-1510 will be administered on Day 1 every 3 weeks
Andere namen:
BHV-1510 will be administered on Day 1 every 2 weeks
Andere namen:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Andere namen:
|
|
Experimenteel: BHV-1510 in combinatie met dosisescalatie van cemiplimab
|
BHV-1510 will be administered on Day 1 every 3 weeks
Andere namen:
BHV-1510 will be administered on Day 1 every 2 weeks
Andere namen:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Andere namen:
cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Phase 1: Number of patients with adverse events (AEs)
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)
Tijdsspanne: Approximately 15 months
|
Based on tolerability and preliminary antitumor activity. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Approximately 15 months
|
|
Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Incidence and severity of AEs, SAEs and DLTs. Severity of AEs will be assessed according to the NCI CTCAE v5.0 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Fase 1 en 2: Maximale plasmaconcentratie (CMAX) van BHV-1510, totaal antilichaam en lading (BHC-0080269)
Tijdsspanne: Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
|
|
Fase 1 en 2: gebied onder de concentratie versus tijdcurve van het einde van de infusie tot de laatste meetbare concentratie (AUCLAST) van BHV-1510, totaal antilichaam en lading
Tijdsspanne: Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
|
|
Fase 1 en 2: gebied onder de concentratie versus tijdcurve over het doseringsinterval (auctau) van BHV-1510, totaal antilichaam en lading
Tijdsspanne: Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
|
|
Fase 1 en 2: Eliminatiehalfwaardetijd (T1/2) van BHV-1510, totaal antilichaam en lading
Tijdsspanne: Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
|
|
Fase 1 en 2: Trogconcentratie (CTROUGH) van BHV-1510, totaal antilichaam en lading
Tijdsspanne: Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
Maximaal 8 tijdstippen, maar niet meer dan 22 dagen in cycli 1 en 3
|
|
|
Fase 2: Effecten van BHV-1510 monotherapie en lading op het QTC-interval met behulp van de correctiemethode van de Fridericia (QTCF), en op andere ECG-parameters (hartslag [HR], PR en QRS-interval)
Tijdsspanne: Ongeveer 15 maanden
|
Ongeveer 15 maanden
|
|
|
Fase 1 en 2: Oppervlak onder de concentratie-tijdcurve geëxtrapoleerd tot oneindig (AUCinf) van BHV-1510, totaal antilichaam en payload
Tijdsspanne: Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1
|
Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1
|
|
|
Fase 1 en 2: Totale lichaamsklaring (CL) na IV-toediening of schijnbare totale lichaamsklaring (CL/F) na SC-toediening van BHV-1510 en totaal antilichaam
Tijdsspanne: Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1 en 3
|
Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1 en 3
|
|
|
Fase 1 en 2: Percentage biobeschikbaarheid (%F) na SC toediening van BHV-1510 en totaal antilichaam
Tijdsspanne: Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1 en 3
|
Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1 en 3
|
|
|
Fase 1 en 2: Verdelingsvolume in steady-state (Vss) na IV-toediening of schijnbaar verdelingsvolume in steady-state (Vss/F) na SC-toediening van BHV-1510 en totale antilichaam
Tijdsspanne: Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1 en 3
|
Tot 8 tijdstippen, maar niet meer dan 22 dagen in Cyclus 1 en 3
|
|
|
Phase 1: ORR
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Duration of Response (DoR)
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1 and 2: Immunogenicity of BHV-1510
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Incidence of ADA at baseline and post-treatment, including ADA titer |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Disease control rate (DCR) for BHV-1510 for monotherapy and in combination with cemiplimab
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Progression free survival (PFS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Overall survival (OS) for BHV-1510 for monotherapy and in combination with cemiplimab
Tijdsspanne: Through study completion, estimated as an average of 47 months
|
OS is defined as the time period from the start of administration to death due to any cause |
Through study completion, estimated as an average of 47 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Chief Medical Officer, Biohaven Pharmaceuticals, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- BHV1510-101 (PBI-410-101)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .